Oncosec Medical Stock Fundamentals
| ONCSDelisted Stock | USD 0.06 0 3.63% |
OncoSec Medical fundamentals help investors to digest information that contributes to OncoSec Medical's financial success or failures. It also enables traders to predict the movement of OncoSec Stock. The fundamental analysis module provides a way to measure OncoSec Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OncoSec Medical stock.
OncoSec |
OncoSec Medical Company Return On Equity Analysis
OncoSec Medical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current OncoSec Medical Return On Equity | -4.1 |
Most of OncoSec Medical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OncoSec Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, OncoSec Medical has a Return On Equity of -4.1017. This is 82.89% lower than that of the Biotechnology sector and 88.75% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
OncoSec Medical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining OncoSec Medical's current stock value. Our valuation model uses many indicators to compare OncoSec Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across OncoSec Medical competition to find correlations between indicators driving OncoSec Medical's intrinsic value. More Info.OncoSec Medical is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value OncoSec Medical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.OncoSec Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OncoSec Medical's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OncoSec Medical could also be used in its relative valuation, which is a method of valuing OncoSec Medical by comparing valuation metrics of similar companies.OncoSec Medical is currently under evaluation in return on equity category among its peers.
OncoSec Fundamentals
| Return On Equity | -4.1 | |||
| Return On Asset | -0.93 | |||
| Current Valuation | 5.6 M | |||
| Shares Outstanding | 5.96 M | |||
| Shares Owned By Insiders | 28.01 % | |||
| Shares Owned By Institutions | 5.83 % | |||
| Number Of Shares Shorted | 192.06 K | |||
| Price To Earning | (3.12) X | |||
| Price To Book | 0.78 X | |||
| EBITDA | (35.92 M) | |||
| Net Income | (34.18 M) | |||
| Cash And Equivalents | 19.48 M | |||
| Cash Per Share | 0.50 X | |||
| Total Debt | 6.17 M | |||
| Debt To Equity | 0.76 % | |||
| Current Ratio | 4.51 X | |||
| Book Value Per Share | (1.85) X | |||
| Cash Flow From Operations | (32.14 M) | |||
| Short Ratio | 0.34 X | |||
| Earnings Per Share | (20.31) X | |||
| Target Price | 110.0 | |||
| Number Of Employees | 40 | |||
| Beta | 2.0 | |||
| Market Capitalization | 1.65 M | |||
| Total Asset | 21.88 M | |||
| Retained Earnings | (285.96 M) | |||
| Working Capital | 8.6 M | |||
| Current Asset | 29.42 M | |||
| Current Liabilities | 3.47 M | |||
| Z Score | -23.08 | |||
| Net Asset | 21.88 M |
About OncoSec Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OncoSec Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OncoSec Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OncoSec Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey. Oncosec Medical operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in OncoSec Stock
If you are still planning to invest in OncoSec Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoSec Medical's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |